Live Chat

Pradaxa Patients: Were You Sufficiently Warned?

Knowing the risks of any decision are essential to making the right choice. What’s generally true in life is also true for choosing the proper strategy for dealing with the potential for blood clots.

 

The Food and Drug Administration (FDA) has initiated a review of the blood thinner Pradaxa – and for good reason. While Pradaxa’s label does mention the risk of bleeding events, FDA officials are legitimately concerned that some labeling insufficiently warned patients, depriving them of the ability to make a responsible choice.

 

You deserve to know the risks associated with your prescription drug regimen. If you’ve been misled by Pradaxa’s product labeling and have experienced adverse health effects, it may be time to talk to the professionals at the law firm of Fears Nachawati. With years of experience, we know how to advise you. Contact our attorneys today for your free consultation. Call 1.866.545.8364 or email mn@fnlawfirm.com

Categories
Drug Litigation

Pradaxa Patients: Were You Sufficiently Warned?